Home 2018-01-31T15:53:20+00:00

 

Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) is a not-for-profit organisation, founded in 2000 with the mission to perform research and provide scientific, economic and regulatory consultancy for innovation in the health sector at European level. The main fields of interest are life sciences and biotechnologies, drug development for small populations (pediatric and rare diseases), research management andmethodology, monitoring, statistics, regulatory, ethics and pharmacovigilance.

Who we are

Activities

Development and application of innovative methodologies in clinical trials for small populations, management of disease registries, execution of studies in the pharmacological field. Find out more.
Development and supervision of dossiers and documentation regarding national and European authorisation procedures for medicinal products. Find out more.
Development and management of all clinical trial phases, which are performed by the Consortium both as a Sponsor and as a Contract Research Organisation (CRO). Find out more.
Educational activities addressed to public bodies, research institutes and private companies, also within CME programmes. Find out more.
Management and participation to medical research projects and consortiums at national and international level. Find out more.
Design and management of registries and drug databases. Find out more.
Research networks aimed to facilitate transfer of know-how and to promote national and international research as well as scientific excellence. Find out more.
CVBF Brochure

On-going Projects

Slide background
Slide background
Slide background
Slide backgroundSlide thumbnail
Closed logo
logo innermed

Latest News

1907, 2018

Europe Biobank week 2018: biosharing for scientific discovery

From 4th until 7th September 2018, a new edition of the Europe Biobank Week (EBW) will take place in Antwerp, Belgium and will be focused on the theme “Biosharing for Scientific Discovery”. The event has been [...]

1907, 2018

SAVE THE DATE. 5-6 September 2018. Paediatric Strategy Forum for Medicinal Product Development of Checkpoint inhibitors for use in combination therapy in paediatric patients

On 5-6 September 2018 EMA (European Medicines Agency) and ACCELERATE – Innovation for children and adolescents with cancer will organize the third multi-stakeholder Paediatric Strategy Forum, that will be focused on checkpoint inhibitors used in combination [...]